Prediction: Buying This Biotech Stock Today Could Set You Up for Life

Mirum Pharmaceuticals (NASDAQ: MIRM) is simply a rising prima successful the biotech satellite that has successfully navigated the riskiest play for tiny drugmakers. Its shares person skyrocketed much than 120% implicit the past 12 months. I foretell that buying this biotech banal contiguous conscionable mightiness acceptable you up for life.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Mirum already markets 3 therapies. Livmarli is approved successful the U.S. and Europe for the attraction of Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), some uncommon familial liver diseases. Ctexli is approved successful the U.S. for the attraction of different uncommon metabolic disorder, Cerebrotendinous Xanthomatosis (CTX). Cholbam is approved successful the U.S. for the attraction of Bile Acid Synthesis Disorders (BASD).

The company's nett merchandise income jumped 50% twelvemonth implicit twelvemonth successful the 4th fourth of 2025. Livmarli led the way, with income soaring 69% to $360 million. This awesome maturation enabled Mirum to make affirmative escaped currency travel successful 2025. Although the company's accrued probe and improvement spending volition origin its escaped currency travel to beryllium antagonistic this year, absorption expects to rapidly instrumentality to affirmative escaped currency travel successful 2027.

Mirum plans to study 4 pivotal readouts from objective studies implicit the adjacent 18 months. The archetypal is coming up soon, with top-line information from a Phase 3 survey evaluating volixibat for the attraction of Primary Sclerosing Cholangitis (PSC) expected successful the 2nd 4th of 2026. Mirum is acceptable to denote Phase 3 information for brelovitug successful the attraction of Hepatitis Delta Virus (HDV) successful the 2nd fractional of this year. It plans to study results from a Phase 3 survey of Livmarli for the attraction of cholestatic pruritus successful the 4th quarter. The institution besides anticipates announcing top-line results successful the archetypal fractional of 2027 for a survey of volixibat successful the attraction of Primary Biliary Cholangitis (PBC).

The highest income estimates for Mirum's pipeline candidates apical $4 billion. The company's marketplace headdress presently hovers astir $5.8 billion. Using the mean price-to-sales ratio for biotech stocks of 6.4, Mirum could beryllium worthy astir $26 cardinal if its therapies fulfill their potential.